Skip to content
Back to USPH

U S Physical Therapy Inc

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
11
Purchases
5
Sales
6
Purchase value
$325.25K
Sale value
$676.75K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Graham D. ReeveCOO
4
Filed Nov 17, 2026Period of report Nov 16, 20260000885978-26-000080
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 16, 2026
Common StockF1F21,792$99.42$178.16K26,762Direct
Filing footnotes · 2
  1. F1The price reported $99.42 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $99.16 to $99.57 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  2. F2Includes 17,488 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as follows: 1,948 shares will vest on November 20, 2026, 1,956 shares will vest on March 6, 2027, 1,636 shares will vest on each of May 20, 2027, August 20, 2027, and November 20, 2027, 1,640 shares will vest on March 6, 2028, 1,130 shares will vest on each of May 20, 2028, August 20, 2028, and November 20, 2028, 1,134 shares will vest on March 6, 2029, 624 shares will vest on each of May 20, 2029, August 20, 2029, and November 20, 2029 and 640 shares will vest on March 6, 2030, if he is an employee of the Company on those dates.
Open on SEC EDGAR
Peter Francis MinanDirector
4
Filed Sep 14, 2026Period of report Jun 12, 20260001193125-26-390608
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseSep 11, 2026
Common StockF3F25.27$79.00$416.333,217.14Direct
PurchaseJun 12, 2026
Common StockF1F20.87$66.50$57.863,211.87Direct
Filing footnotes · 3
  1. F1Represents a fractional share acquired through the automatic reinvestment of cash dividends in the Reporting Person's brokerage account. This transaction was inadvertently not reported previously and is being reported on this Form 4.
  2. F2Includes 1,153 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as follows: 576 shares on November 20, 2026 and 577 shares on March 6, 2027, if he is a director of the Company on those dates.
  3. F3Represents shares acquired through automatic reinvestment of cash dividends in the Reporting Person's brokerage account.
Open on SEC EDGAR
Peter Francis MinanDirector
4
Filed Jun 10, 2026Period of report Jun 8, 20260001193125-26-266197
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseJun 9, 2026
Common StockF1288$61.50$17.71K3,211Direct
PurchaseJun 8, 2026
Common StockF1492$63.14$31.06K2,923Direct
Filing footnotes · 1
  1. F1Includes 2,306 shares which were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,153 shares on August 20, 2026, 576 shares on November 20, 2026 and 577 shares on March 6, 2027, if he is a director of the Company on those dates.
Open on SEC EDGAR
Graham D. ReeveCOO
4
Filed Mar 12, 2026Period of report Mar 11, 20260001193125-26-104315
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 11, 2026
Common StockF1F2662$78.86$52.21K30,078Direct
Filing footnotes · 2
  1. F1The price reported ($78.86) is the weighted average price. The shares were sold in multiple transactions at prices ranging from $78.82 to $79.82 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  2. F2Includes 21,384 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restriction lapse as follows: 1,948 shares will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 1,956 shares will vest on March 6, 2027, 1,636 shares will vest on each of May 20, 2027, August 20, 2027, and November 20, 2027, 1,640 shares will vest on March 6, 2028, 1,130 shares will vest on each of May 20, 2028, August 20, 2028, and November 20, 2028, 1,134 shares will vest on March 6, 2029, 624 shares will vest on each of May 20, 2029, August 20, 2029, and November 20, 2029 and 640 shares will vest on March 6, 2030, if he is an employee of the Company on those dates.
Open on SEC EDGAR
Graham D. ReeveCOO
4
Filed Mar 11, 2026Period of report Mar 6, 20260001193125-26-102296
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 9, 2026
Common Stock1$78.52$78.520IndirectReeve Trust
SaleMar 6, 2026
Common Stock1,807$82.25$148.63K1IndirectReeve Trust
Filing footnotes · 1
  1. F1Includes 21,384 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restriction lapse as follows: 1,948 shares will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 1,956 shares will vest on March 6, 2027, 1,636 shares will vest on each of May 20, 2027, August 20, 2027, and November 20, 2027, 1,640 shares will vest on March 6, 2028, 1,130 shares will vest on each of May 20, 2028, August 20, 2028, and November 20, 2028, 1,134 shares will vest on March 6, 2029, 624 shares will vest on each of May 20, 2029, August 20, 2029, and November 20, 2029 and 640 shares will vest on March 6, 2030, if he is an employee of the Company on those dates.
Open on SEC EDGAR
Richard BinsteinEVP Gen'l Counsel & Secretary
4
Filed Mar 9, 2026Period of report Mar 6, 20260001193125-26-098618
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 6, 2026
Common StockF13,000$81.64$244.92K24,867Direct
Filing footnotes · 1
  1. F1Includes 21,070 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restriction lapse as to 1,870 shares will vest on each of May 20, 2026, August 20, 2026 and November 20, 2026, 1,876 shares will vest on March 6, 2027, 1,636 shares will vest on each of May 20, 2027, August 20, 2027, and November 20, 2027, 1,640 shares will vest on March 6, 2028, 1,130 shares will vest on each of May 20, 2028, August 20, 2028, and November 20, 2028, 1,134 shares will vest on March 6, 2029, 624 shares will vest on each of May 20, 2029, August 20, 2029, and November 20, 2029 and 640 shares will vest on March 6, 2030, if he is an employee of the Company on those dates.
Open on SEC EDGAR
Graham D. ReeveCOO
4
Filed Nov 25, 2025Period of report Nov 24, 20250001193125-25-297192
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 24, 2025
Common StockF1F2743$71.01$52.76K20,740Direct
Filing footnotes · 2
  1. F1The price reported $71.01 is the weighted average price. The shares were sold in multiple transactions at prices ranging from $71.01 to $71.31 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  2. F2Includes 13,348 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,964 shares on March 6, 2026, 1,324 shares on each of May 20, 2026, August 20, 2026, and November 20, 2026, 1,332 shares on March 6, 2027, 1,012 shares on each of May 20, 2027, August 20, 2027, and November 20, 2027, 1,016 shares on March 6, 2028, 506 shares of each on May 20, 2028, August 20, 2028, and November 20, 2028, and 510 shares on March 6, 2029, if he is an employee of the Company on those dates.
Open on SEC EDGAR
Kathleen A GilmartinDirector
4
Filed Nov 24, 2025Period of report Nov 20, 20250001193125-25-293697
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 20, 2025
Common StockF14,000$69.00$276.00K24,786Direct
Filing footnotes · 1
  1. F1Includes 471 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. These shares will fully vest on March 6, 2026 if she remains as a member of the Board of Directors of the Company on that date.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.